Lannett Kicks Off Insulin Glargine Trial

Firm Eyes 2023 Filing And 2024 Launch For US Interchangeable Biosimilar Lantus Rival

Lannett has delivered on its promise of kicking off a pivotal clinical trial for its proposed interchangeable biosimilar rival to Lantus by the end of March, as it eyes a 2023 filing and 2024 launch in the US for the insulin glargine product on which it has partnered with HEC.

Road years 2022 2023 2024
The road to an insulin glargine launch stretches to 2024 for Lannett • Source: thodsapol thongdeekhieo / Alamy Stock Photo

Having promised to begin by the end of March a pivotal clinical trial for the Lantus (insulin glargine) biosimilar candidate on which it is partnered with China’s HEC, Lannett has delivered on the milestone and confirmed expected US filing and launch dates for the product.

“The first subject in the pivotal trial has been dosed and we believe top line results of the study will...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Biosimilars

More from Products

  • For Generics, A Victory Lap – And A Warning – On Drug Shortages

    Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

  • GB-Free-Company-The Secret to Walking More: It’s Not Counting Steps

    We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.

  • Biocon And Teva Sign Up To Biosimilars Forum

    Teva and Biocon Biologics have become the latest firms to sign up to the Biosimilars Forum industry association in the US.